Skip to Content
MilliporeSigma
All Photos(1)

Documents

MABE416

Sigma-Aldrich

Anti-Cisplatin DNA Adducts Antibody, clone ICR4

clone 1CR4, from rat

Synonym(s):

CP9/19, Cisplatin DNA modification

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rat

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

1CR4, monoclonal

species reactivity

human

technique(s)

ELISA: suitable
dot blot: suitable
immunohistochemistry: suitable

isotype

IgG2aκ

shipped in

wet ice

target post-translational modification

unmodified

Related Categories

General description

Cisplatin adducts are Guanine-Guanine (GG) DNA intrastrand cross links caused by the chemical compound Cisplatin. Cisplatin is used as a chemotherapy agent that contains platinum. The crosslinking of the DNA triggers apoptosis in the effected cell. Cisplatin is particularly effective in certain cancers such as testicular cancer. Unfortunately like most chemotherapy agents Cisplatin has many side effects and cancer cells typically will develop resistance to the drug after a period of time. Clone ICR4 was formerly known as clone CP9/19.

Specificity

This antibody demonstrates specificity for cisplatin modified DNA.

Immunogen

Cisplatin modified native DNA.

Application

Detect Cisplatin adducts using this rat monoclonal antibody, Anti-Cisplatin DNA Adducts Antibody, clone ICR4 validated for use in Dot Blot, ELISA & IHC.
ELISA Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in ELISA (Tilby, M. J., et al. (1991). Cancer Res. 51(1):123-129.; Kothandapani, A., et al. (2011). J Biol Chem. 286(16):14564-14574.; Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.; Strobeck, M. W., et al. (2000). Proc Natl Acad Sci USA. 97(14):7748-7753.; Kothandapani, A., et al. (2012). Exp Cell Res. 18(16):1973-1986.).

Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in Head and Neck Squamous Cell Carcinoma tissues. (Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology

Quality

Evaluated by Dot Blot in untreated and Cisplatin treated DNA from HeLa cell lysates.

Dot Blot Analysis: A 1:1,000 dilution of this antibody detected Cisplatin DNA Adducts in 1.0 and 0.5 µg of Cisplatin treated DNA from HeLa cell lysates.

Physical form

Format: Purified
Protein G Purified
Purified rat monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Cisplatin United States Pharmacopeia (USP) Reference Standard

USP

1134357

Cisplatin

Cisplatin British Pharmacopoeia (BP) Reference Standard

BP809

Cisplatin

M W Strobeck et al.
Proceedings of the National Academy of Sciences of the United States of America, 97(14), 7748-7753 (2000-07-08)
The antiproliferative action of the retinoblastoma tumor suppressor protein, RB, is disrupted in the majority of human cancers. Disruption of RB activity occurs through several disparate mechanisms, including viral oncoprotein binding, deregulated RB phosphorylation, and mutation of the RB gene.
Anbarasi Kothandapani et al.
The Journal of biological chemistry, 286(16), 14564-14574 (2011-03-02)
Using isogenic mouse embryonic fibroblasts and human cancer cell lines, we show that cells defective in base excision repair (BER) display a cisplatin-specific resistant phenotype. This was accompanied by enhanced repair of cisplatin interstrand cross-links (ICLs) and ICL-induced DNA double
Anbarasi Kothandapani et al.
Experimental cell research, 318(16), 1973-1986 (2012-06-23)
Chromatin remodeling complex SWI/SNF plays important roles in many cellular processes including transcription, proliferation, differentiation and DNA repair. In this report, we investigated the role of SWI/SNF catalytic subunits Brg1 and Brm in the cellular response to cisplatin in lung
Yonggen Zou et al.
Oncology letters, 15(1), 1097-1102 (2018-02-06)
As an important chemotherapeutic agent for the treatment of osteosarcoma, the effectiveness of cisplatin is considered to be due to its unique properties, which allow it to penetrate the cell membrane and form various DNA-platinum adducts, resulting in genetic alterations
M J Welters et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 10(1), 97-103 (1999-03-17)
Response to cisplatin-therapy is assumed to be related to the formation of platinum (Pt)-DNA adducts. Measurement of these adducts prior to therapy could be of value to improve cisplatin based cancer therapy. We determined Pt-GG and Pt-AG adduct levels by

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service